Cambrex Kicks Off Major $120 Million Expansion in Charles City, Iowa

Cambrex's New Chapter in Charles City

Cambrex, a leading global CDMO (Contract Development and Manufacturing Organization), has officially begun construction on a substantial expansion project valued at $120 million at its facility in Charles City, Iowa. The groundbreaking event took place on October 29, 2026, and was attended by key leaders, employees, local officials, and community members, marking an important milestone not just for Cambrex, but also for the city that has housed the facility for a century.

This ambitious expansion will add an impressive 160,000 liters of manufacturing capacity, increasing the total capacity of the Charles City plant by approximately 25%. This enhancement will bring the total capacity close to a million liters and will significantly bolster Cambrex’s ability to support the development and commercial manufacturing of Active Pharmaceutical Ingredients (APIs), particularly for small molecules and synthetic peptides.

The project is slated for completion in the fourth quarter of 2028. According to Claudio Russolo, Cambrex's Chief Operating Officer and incoming CEO, this expansion marks a pivotal point in Cambrex’s ongoing investment in U.S. manufacturing, particularly emphasizing the importance of the Charles City site. As the facility celebrates its centennial anniversary, the expansion serves as a testament to both its longstanding legacy and its critical role in Cambrex's future endeavors.

The Charles City facility specializes in offering comprehensive services for the development and manufacturing of APIs, including small molecules, synthetic peptides, and pharmaceutical intermediates. It provides crucial support for projects spanning from clinical development stages to large-scale commercial production. This expansion is designed to leverage both the existing infrastructure and technical expertise of the facility while enabling additional capacity to meet increasing customer demand.

Over the past 45 years, Cambrex has built a reputation as a trusted partner in the pharmaceutical industry, serving clients throughout North America and Europe with a diverse range of technologies and specialized capabilities in drug substances. From continuous flow and controlled substances to complex synthesis and solid-state sciences, Cambrex offers a well-rounded portfolio to meet the evolving needs of its clients.

As Cambrex looks ahead, this new expansion is not just about increasing capacity; it's about ensuring that the company remains at the forefront of the pharmaceutical manufacturing industry. By enhancing their manufacturing capabilities, Cambrex reaffirms its commitment to supporting clients' transition from development phases to market readiness effectively.

In summary, Cambrex's $120 million expansion in Charles City represents a significant investment in not only the local community but also in the future of pharmaceutical manufacturing in the United States. This milestone aptly reflects a synergy between a rich history of operational excellence and a dedicated pursuit of innovation, ultimately driving both economic growth and improved healthcare solutions.